tau imaging news gives memory clinics a second FDA-cleared tau PET option for Alzheimer's workups. For patients with cognitive impairment, it may sharpen diagnosis, staging, and anti-amyloid treatment decisions after amyloid testing.
Tau PET is a brain scan that maps tau tangles, twisted proteins that damage brain cells. The change does not make tau scans routine screening. It gives doctors another tool for complex cases where amyloid results and symptoms need clearer staging.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What changed in 2026
- Why earlier signal matters
- Limits patients should know
- Will your clinic offer tau PET?
What changed in 2026
Lantheus announced on Aug. 14, 2026, FDA approval of Tauklarify for brain PET in adults with cognitive impairment evaluated for Alzheimer's the FDA approval notice. The tracer, florquinitau F 18 and formerly MK-6240, identifies tau tangle pathology. Pharmacy Times noted it is the second FDA-cleared tau tracer after Eli Lilly's Tauvid in 2020.
Clinics now can move beyond one approved tau agent. Pharmacy Times also reported blinded-read testing across 617 scans with five readers. For patients, more supply means less dependence on a single product. Access still depends on clinic ordering, PET availability, and insurance review.
Why earlier signal matters
Being Patient, reporting on a Lancet head-to-head study, found MK-6240 reached positivity at about 53 Centiloids of amyloid versus about 81 for Tauvid the head-to-head comparison. It also picked up tangles confined to the medial temporal lobe. Being Patient reported in September 2026 that the tracer better separated Alzheimer-related impairment with amyloid present from non-Alzheimer impairment.
That distinction helps explain mixed memory symptoms. It may also flag who could benefit most from anti-amyloid drugs. Earlier signal does not mean earlier screening for everyone. It matters most when doctors must decide if Alzheimer's drives current impairment.
Limits patients should know
The Lantheus prescribing information warns that testing focused on amyloid-negative unimpaired people versus amyloid-positive impaired people, so accuracy may drop earlier in disease the prescribing information. A negative scan does not exclude tau. A positive scan alone does not confirm Alzheimer's disease. Use is not established for non-Alzheimer tauopathies, according to Lantheus and Enigma reporting via BioSpace.
Patients must avoid smoking and other CYP1A2 inducers for 7 days before dosing. Patients who lactate must pause for 4 hours after injection. Tell the clinic about smoking, new medicines, supplements, and breastfeeding. Those details affect scheduling and safety.
Will your clinic offer tau PET?
The 2025 Alzheimer's Association and SNMMI appropriate-use criteria, published in the Journal of Nuclear Medicine, rate tau PET appropriate in 5 defined scenarios. The role is generally after amyloid confirmation.
The goals are staging and treatment decisions, not routine screening. Ask the memory clinic: Bring a medicine list, smoking history, and breastfeeding status to that visit.
- Is my amyloid status already confirmed
- Would tau staging change diagnosis or treatment
- What preparation, radiation exposure, and costs apply
- When and how will we review scan limits
You Might Also Like
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: What Memory Clinic Patients Should Know About the News
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: What Memory Clinic Patients Should Know About the News
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: What Memory Clinic Patients Should Know About the News
